Top

Cancer Chemotherapy and Pharmacology

Published in:

01-08-2005 | Original Article

Human cells deficient in transcription-coupled repair show prolonged activation of the Jun N-terminal kinase and increased sensitivity following cisplatin treatment

Authors: J. Todd Bulmer, Natalie J. Zacal, Andrew J. Rainbow

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2005

Abstract

Purpose

The Jun N-terminal kinases (JNKs) are activated by many biological, physical, and chemical stimuli, including the chemotherapeutic agent cisplatin. The primary pathway that repairs cisplatin-DNA adducts is nucleotide excision repair (NER). Xeroderma pigmentosum (XP) cells from complementation group C (XP-C) are competent in the transcription-coupled repair (TCR) pathway of NER but deficient in global genomic repair (GGR), Cockayne’s syndrome (CS) cells are deficient in TCR but have normal GGR, and XP-A cells are deficient in both TCR and GGR. We used NER-deficient human fibroblasts to study the role of DNA damage in the activation of JNK and cell death following cisplatin treatment.

Materials and methods

JNK-1 activity and clonogenic survival were examined in normal and NER-deficient human fibroblasts following cisplatin treatment.

Results

Cisplatin induced a transient increase in JNK-1 activity of about tenfold in normal and XP-C fibroblasts, which declined to about two- to threefold 24 h after treatment. In contrast, the activation of JNK-1 was persistent in XP-A and CS fibroblasts at 24 h after treatment and CS cells and XP-A cells, but not XP-C cells, were more sensitive to cisplatin than normal cells.

Conclusions

These results suggest that a deficiency in the TCR pathway of NER results in amplified and prolonged JNK activation due to persistent damage within the transcribed strand of active genes. Further, it is this amplified and prolonged JNK activation that correlates with cisplatin-induced cell death.

Aboussekhra A, Biggerstaff M, Shivji MK, Vilpo JA, Moncollin V, Podust VN, Protic M, Hubscher U, Egly JM, Wood RD (1995) Mammalian DNA nucleotide excision repair reconstituted with purified protein components. Cell 80:859–868

Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R, Howell SB (1996) Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56:3087–3090

Bingham JP, Hartley JA, Souhami RL, Grimaldi KA (1996) Strand-specific measurement of cisplatin-induced DNA damage and repair using quantitative PCR. Nucleic Acids Res 24:987–989

Blattner C, Bender K, Herrlich P, Rahmsdorf HJ (1998) Photoproducts in transcriptionally active DNA induce signal transduction to the delayed UV-responsive genes for collagenase and metallothionein. Oncogene 16:2827–2834

Bregman DB, Halaban R, van Gool AJ, Henning KA, Friedberg EC, Warren SL (1996) UV-induced ubiquitination of RNA polymerase II: a novel modification deficient in Cockayne syndrome cells. Proc Natl Acad Sci U S A 93:11586–11590

Brown R, Clugston C, Burns P, Edlin A, Vasey P, Vojtesek B, Kaye SB (1993) Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 55:678–684

Bulavin DV, Saito S, Hollander MC, Sakaguchi K, Anderson CW, Appella E, Fornace AJ Jr (1999) Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J 18:6845–6854

Bulmer JT, Davis K, Rainbow AJ (1996) Host cell reactivation of cisplatin-treated adenovirus is reduced in nucleotide excision repair deficient mammalian cells and several human tumour cells. Int J Oncol 9:1121–1127

Buschmann T, Potapova O, Bar-Shira A, Ivanov VN, Fuchs SY, Henderson S, Fried VA, Minamoto T, Alarcon-Vargas D, Pincus MR, Gaarde WA, Holbrook NJ, Shiloh Y, Ronai Z (2001) Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol Cell Biol 21:2743–2754

10.

Ciccarelli RB, Solomon MJ, Varshavsky A, Lippard SJ (1985) In vivo effects of cis- and trans-diamminedichloroplatinum(II) on SV40 chromosomes: differential repair, DNA-protein cross-linking, and inhibition of replication. Biochemistry 24:7533–7540

11.

Cui W, Yazlovitskaya EM, Mayo MS, Pelling JC, Persons DL (2000) Cisplatin-induced response of c-jun N-terminal kinase 1 and extracellular signal-regulated protein kinases 1 and 2 in a series of cisplatin-resistant ovarian carcinoma cell lines. Mol Carcinog 29:219–228

12.

D‘Andrea AD, Grompe M (2003) The Fanconi anaemia/BRCA pathway. Nat Rev 3:23–34

13.

de Boer J, Hoeijmakers JH (2000) Nucleotide excision repair and human syndromes. Carcinogenesis 21:453–460

14.

Dempke W, Voigt W, Grothey A, Hill BT, Schmoll HJ (2000) Cisplatin resistance and oncogenes—a review. Anticancer Drugs 11:225–236

15.

Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, Karin M, Davis RJ (1994) JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76:1025–1037

16.

Devary Y, Rosette C, DiDonato JA, Karin M (1993) NF-kappa B activation by ultraviolet light not dependent on a nuclear signal. Science 261:1442–1445

17.

Dhar V, Adler V, Lehmann A, Ronai Z (1996) Impaired jun-NH2-terminal kinase activation by ultraviolet irradiation in fibroblasts of patients with Cockayne syndrome complementation group B. Cell Growth Differ 7:841–846

18.

Dijt FJ, Fichtinger-Schepman AM, Berends F, Reedijk J (1988) Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. Cancer Res 48:6058–6062

19.

Fuchs SY, Adler V, Buschmann T, Yin Z, Wu X, Jones SN, Ronai Z (1998) JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev 12:2658–2663

20.

Fuchs SY, Adler V, Pincus MR, Ronai Z (1998) MEKK1/JNK signalling stabilizes and activates p53. Proc Natl Acad Sci U S A 95:10541–10546

21.

Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y (2002) Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 62:4899–4902

22.

Gjerset RA, Lebedeva S, Haghighi A, Turla ST, Mercola D (1999) Inhibition of the Jun kinase pathway blocks DNA repair, enhances p53-mediated apoptosis and promotes gene amplification. Cell Growth Differ 10:545–554

23.

Hayakawa J, Ohmichi M, Kurachi H, Ikegami H, Kimura A, Matsuoka T, Jikihara H, Mercola D, Murata Y (1999) Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J Biol Chem 274:31648–31654

24.

Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49–53

25.

Ip YT, Davis RJ (1998) Signal transduction by the c-Jun N-terminal kinase (JNK)—from inflammation to development. Curr Opin Cell Biol 10:205–219

26.

Jordan P, Carmo-Fonseca M (2000) Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 57:1229–1235

27.

Kantor GJ, Barsalou LS, Hanawalt PC (1990) Selective repair of specific chromatin domains in UV-irradiated cells from xeroderma pigmentosum complementation group C. Mutat Res 235:171–180

28.

Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS (1988) Overexpression of metallothionein confers resistance to anticancer drugs. Science 241:1813–1815

29.

Kharbanda S, Ren R, Pandey P, Shafman TD, Feller SM, Weichselbaum RR, Kufe DW (1995) Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature 376:785–788

30.

Ko LJ, Prives C (1996) p53: puzzle and paradigm. Genes Dev 10:1054–1072

31.

Ljungman M, Zhang F, Chen F, Rainbow AJ, McKay BC (1999) Inhibition of RNA polymerase II as a trigger for the p53 response. Oncogene 18:583–592

32.

Loehrer PJ, Einhorn LH (1984) Drugs five years later. Cisplatin. Ann Intern Med 100:704–713

33.

Malaise EP, Fertil B, Deschavanne PJ, Chavaudra N, Brock WA (1987) Initial slope of radiation survival curves is characteristic of the origin of primary and established cultures of human tumor cells and fibroblasts. Radiat Res 111:319–333

34.

Mansouri A, Ridgway LD, Korapati AL, Zhang G, Tian L, Wang Y, Siddik ZH, Mills GB, Claret FX (2003) Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 278:19245–19256

35.

McKay BC, Ljungman M, Rainbow AJ (1998) Persistent DNA damage induced by ultraviolet light inhibits p21waf1 and bax expression: implications for DNA repair, UV sensitivity and the induction of apoptosis. Oncogene 17:545–555

36.

McKay BC, Ljungman M, Rainbow AJ (1999) Potential roles for p53 in nucleotide excision repair. Carcinogenesis 20:1389–1396

37.

McKay BC, Chen F, Clarke ST, Wiggin HE, Harley LM, Ljungman M (2001) UV light-induced degradation of RNA polymerase II is dependent on the Cockayne’s syndrome A and B proteins but not p53 or MLH1. Mutat Res 485:93–105

38.

Nehme A, Baskaran R, Nebel S, Fink D, Howell SB, Wang JY, Christen RD (1999) Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. Br J Cancer 79:1104–1110

39.

Persons DL, Yazlovitskaya EM, Cui W, Pelling JC (1999) Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res 5:1007–1014

40.

Potapova O, Haghighi A, Bost F, Liu C, Birrer MJ, Gjerset R, Mercola D (1997) The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J Biol Chem 272:14041–14044

41.

Rosenberg B (1985) Fundamental studies with cisplatin. Cancer 55:2303–2316

42.

Sanchez-Perez I, Murguia JR, Perona R (1998) Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 16:533–540

43.

Sanchez-Perez I, Perona R (1999) Lack of c-Jun activity increases survival to cisplatin. FEBS Lett 453:151–158

44.

Sanchez-Perez I, Martinez-Gomariz M, Williams D, Keyse SM, Perona R (2000) CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin. Oncogene 19:5142–5152

45.

Sanchez-Prieto R, Rojas JM, Taya Y, Gutkind JS (2000) A role for the p38 mitogen-activated protein kinase pathway in the transcriptional activation of p53 on genotoxic stress by chemotherapeutic agents. Cancer Res 60:2464–2472

46.

Scanlon KJ, Kashani-Sabet M, Tone T, Funato T (1991) Cisplatin resistance in human cancers. Pharmacol Ther 52:385–406

47.

Schaeffer HJ, Weber MJ (1999) Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 19:2435–2444

48.

Schreiber M, Kolbus A, Piu F, Szabowski A, Mohle-Steinlein U, Tian J, Karin M, Angel P, Wagner EF (1999) Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev 13:607–619

49.

Sherman SE, Lippard SJ (1987) Structural aspects of platinum anticancer drug interactions with DNA. Chem Rev 87:1153–1181

50.

Tanaka K, Kawai K, Kumahara Y, Ikenaga M, Okada Y (1981) Genetic complementation groups in Cockayne syndrome. Somatic Cell Genet 7:445–455

51.

Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, Mok SC, D’Andrea AD (2003) Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumours. Nat Med 9:568–574

52.

Vandier D, Calvez V, Massade L, Gouyette A, Mickley L, Fojo T, Rixe O (2000) Transactivation of the metallothionein promoter in cisplatin-resistant cancer cells: a specific gene therapy strategy. J Natl Cancer Inst 92:642–647

53.

Venema J, Mullenders LH, Natarajan AT, van Zeeland AA, Mayne LV (1990) The genetic defect in Cockayne syndrome is associated with a defect in repair of UV-induced DNA damage in transcriptionally active DNA. Proc Natl Acad Sci U S A 87:4707–4711

54.

Venema J, van Hoffen A, Karcagi V, Natarajan AT, van Zeeland AA, Mullenders LH (1991) Xeroderma pigmentosum complementation group C cells remove pyrimidine dimers selectively from the transcribed strand of active genes. Mol Cell Biol 11:4128–4134

55.

Wang X, Martindale JL, Holbrook NJ (2000) Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 275:39435–39443

56.

Yamaizumi M, Sugano T (1994) UV-induced nuclear accumulation of p53 is evoked through DNA damage of actively transcribed genes independent of the cell cycle. Oncogene 9:2775–2784

57.

Yazlovitskaya EM, DeHaan RD, Persons DL (2001) Prolonged wild-type p53 protein accumulation and cisplatin resistance. Biochem Biophys Res Commun 283:732–737

58.

Zamble DB, Mu D, Reardon JT, Sancar A, Lippard SJ (1996) Repair of cisplatin–DNA adducts by the mammalian excision nuclease. Biochemistry 35:10004–10013

59.

Zanke BW, Boudreau K, Rubie E, Winnett E, Tibbles LA, Zon L, Kyriakis J, Liu FF, Woodgett JR (1996) The stress-activated protein kinase pathway mediates cell death following injury induced by cis-platinum, UV irradiation or heat. Curr Biol 6:606–613

Title: Human cells deficient in transcription-coupled repair show prolonged activation of the Jun N-terminal kinase and increased sensitivity following cisplatin treatment
Authors: J. Todd Bulmer
Natalie J. Zacal
Andrew J. Rainbow
Publication date: 01-08-2005
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 2/2005
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-004-0984-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2005

Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog

A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer

HERG K+ channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin

Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5′-deoxy-5-fluorouridine (5′-DFUR)

Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies

In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative

Keynote webinar | Spotlight on antibody–drug conjugates in cancer